4 Results for "

obstructive sleep apnea

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "obstructive sleep apnea" in MCE Product Catalog:

Cat. No.: HY-159639
CAS No.: 2642235-06-9
Target:  

Androgen Receptor

Research Areas:  

Infection Others

BAY-2925976 is an ARα2C antagonist. BAY-2925976 acts on G protein-coupled presynaptic autoreceptors and inhibits norepinephrine release at low endogenous norepinephrine concentrations. BAY-2925976 can be used in research on obstructive sleep apnea (OSA) .
loading...
    loading...
Cat. No.: HY-145554
CAS No.: 2256770-44-0
Purity:  99.67%
Target:  

Drug Derivative

Research Areas:  

Others

Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1).
loading...
    loading...
Cat. No.: HY-123836
CAS No.: 936626-07-2
Target:  

Histamine Receptor

Research Areas:  

Neurological Disease

MK-7288 is a histamine H3 receptor inverse agonist. MK-7288 can prolong sleep latency in the Maintain Wake Test (MWT). MK-7288 can be used in research on obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS) .
loading...
    loading...
Cat. No.: HY-L087
3,784 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,784 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.